Pharmaceutical industry news

Pancreatic Cancer: New FDA-Approved Drug Doubles Survival Rates

UAB startup brings decades of research to the future of lung care

Application of Predictive Modeling in the Development of Amorphous Solid Dispersions

Summit's Ivonescimab Beats Merck's Keytruda on Survival in Chinese Lung Cancer Trial

10x Genomics wins latest round in Parse patent dispute

Psilocybin proves promising in neuropathic pain mouse study

Pancreatic Cancer Drug Shows Early Promise For Lung Cancer Patients

Ultragenyx Pharmaceutical Target of Unusually Large Options Trading (NASDAQ:RARE)

How A National Licensure Standard Would Change Wholesaler Operations

Ian McCaffery Bio | | Xaira Therapeutics

Xaira Therapeutics

$40M gift to UBC is the largest ever to a Canadian school of nursing

The long shadow of early sugar consumption. Plus a reality check on FDA approval

Himalayas-1: Bayer and ORIC Double Down on Prostate Cancer With New Phase 3 Combo Trial

House BIOTech caucus is weighing IP security and AI-enabled biotech policy

Russian forces launch two attacks on Teva Ukraine pharmaceutical company warehouse

Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US

Pharmaceutical Company In Senegal Produces First African-Made Clinical Treatment For Sickle Cell

The EU Pharmaceutical Legislation: Why Regulatory Reform Matters for IP Teams

How Does Zurzuvae Compare With Other Antidepressants for Postpartum Depression?

FDA Issues Year-Long SOP For Mahaprasad, Langar Ahead Of Festivals To Ensure Food Safety

Biotech Stocks To Follow Now - September 3rd

Erasmus Days: Discover the 2026 Programme!

FDA Seeks Public Input to Advance Development of Botanical Drug Products

Ultragenyx's Apazunersen Fails Phase 3 Angelman Syndrome Trial

FDA orders recall of Arcan Bitters over undeclared drug substance

Kali Therapeutics Receives U.S. FDA Clearance for KT501 Investigational New Drug Application

TwinStrand’s $245M win signals growing value of biotech patent monetisation

Colombia after the earthquake: volunteering instead of a research trip

Nottingham professor awarded International Pharmaceutical Federation Fellowship

RIKEN Mathematics & AI Symposium 2026

Why Is Summit Therapeutics Stock Soaring Today? - Summit Therapeutics (NASDAQ:SMMT)

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

How UBC supports students with specific dietary needs and cultural food preferences

Maha FDA unveils permanent food safety calendar for festivals

Seattle scientists launch $95 million AI biology effort

Avacopan Safety Concerns Grow Amid Liver Injury Signals, reports US registry analysis

IND Safety Reporting: What Sites Need to Submit

Controversial Drug Suspended Due to Trial Irregularities

From Eid to Diwali, Maharashtra FDA, led by Tukaram Munde, announces year-round rules for festivals

Sweets, cooking oil and community feasts to face stricter checks as Maharashtra FDA announces four-stage food safety system for festivals

Biotechnology firm to double local workforce after leasing larger space

ESC 2026: oral and injectable GLP-1 comparisons under the spotlight

Recognising animal flu viruses before the threat of a pandemic

£2 million investment to advance materials innovation

Hyperglycemic stress aggravates diabetic retinopathy and nephropathy by promoting cilium disassembly via a deacetylation- and methylation-mediated regulatory mechanism

Carlos Pérez Gonzàlez lauréat de la bourse européenne ERC Starting Grant

Ultragenyx Shares Drop Following Failed Phase III Clinical Trial

A first look into the heart of the Milky Way

Eledon files islet cell transplant application, plans Phase 3 kidney trial

Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 12-Month Low After Analyst Downgrade

Keep your vaccines healthy poster and magnet

Information for health professionals on vaccine ordering and storage.

Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $37.00 Price Target at Canaccord Genuity Group

HDA Proposes Two-Year Timeline for National Pharmaceutical Distributor Licensure

Maharashtra FDA Tests Over 30,000 Food Samples, More Than 15,000 Found Below Standards

AbbVie bispecific shows promise in ph. 3 multiple myeloma trial

RARE Stock Craters As Aspire Trial Failure Triggers Reset

AbbVie’s experimental treatment cut the risk of disease getting worse or death 60% versus standard therapies.

William Blair Downgrades Ultragenyx Pharmaceutical (NASDAQ:RARE) to Market Perform

World Bio Market Insights: Scaling without Cells